Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome is entering into a phase 3 trial after a successful phase II trial in Europe. The primary efficacy endpoint of the phase 2 trial was the reduction of bowel movements from baseline in patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy.
The phase III trial will be available at UCSF and Stanford.
Stanford is currently recruiting patients,
please click here for more information.
To learn more about the clinical trial please visit clinicaltrials.gov page.
To read more about the results from the phase 2 trial please visit the Lexicon-pharma webstie.